Literature DB >> 1398921

The glucuronoxylomannan of Cryptococcus neoformans serotype A is a type 2 T-cell-independent antigen.

J B Sundstrom1, R Cherniak.   

Abstract

The humoral immune response of inbred mice to immunization with the glucuronoxylomannan (GXM) of Cryptococcus neoformans was investigated both serologically and in plaque-forming cells (PFCs). The T-helper-cell-independent quality of the GXM was demonstrated by using BALB/c nu/nu mice. Primary and secondary dose responses to three antigenic forms of GXM, (i) the native antigen, (ii) a GXM-bovine serum albumin protein conjugate, and (iii) a cryptococcal whole-cell vaccine, revealed a lack of isotype class switching and anamnestic responses. Both the levels of complement-fixing anti-GXM antibody in serum and the PFC responses in the athymic mice showed no significant differences from those in the wild-type controls. However, T cells are involved in the suppression of the primary response to GXM. When BALB/cBy mice were given rabbit anti-mouse thymocyte serum along with 0.5 microgram of GXM, both antibody levels in serum and PFC responses were significantly increased over those of control mice that received GXM and normal rabbit serum. In addition, T cells were also shown to enhance the primary immune response to GXM. BALB/cBy mice were given GXM and anti-mouse thymocyte serum on day 1. On day 2, the experimental group was given anti-mouse thymocyte serum and the control group was given saline. On day 5, comparison of the PFC responses and anti-GXM antibody titers of the two groups revealed a significant increase in the immune response of the control over the experimental group. The type 2 T-cell-independent quality of GXM was also demonstrated in CBA/cHN xid mice. These mice lack the Lyb+ subset of B cells and are unable to respond to type 2 T-independent antigens but respond normally to type 1 T-independent antigens. Type III pneumococcal polysaccharide, a type 2 T-independent antigen, was used as a negative control, and trinitrophenyl-lipopolysaccharide, a type 1 T-independent antigen, was used as a positive control. The CBA/cHN xid mice failed to respond to either type III pneumococcal polysaccharide or GXM but did not respond to immunization with trinitrophenyl-lipopolysaccharide. BALB/cBy mice responded normally to all three antigens.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1398921      PMCID: PMC257439          DOI: 10.1128/iai.60.10.4080-4087.1992

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  43 in total

1.  Application of transformations to normalize the distribution of plaque-forming cells.

Authors:  C F Gottlieb
Journal:  J Immunol       Date:  1974-07       Impact factor: 5.422

2.  Further improvements in the plaque technique for detecting single antibody-forming cells.

Authors:  A J Cunningham; A Szenberg
Journal:  Immunology       Date:  1968-04       Impact factor: 7.397

3.  Direct evidence for the involvement of T suppressor cells in the expression of low-dose paralysis to type III pneumococcal polysaccharide.

Authors:  P J Baker; D F Amsbaugh; P W Stashak; G Caldes; B Prescott
Journal:  J Immunol       Date:  1982-03       Impact factor: 5.422

4.  Fractionation and characterization of galactoxylomannan from Cryptococcus neoformans.

Authors:  S H Turner; R Cherniak; E Reiss
Journal:  Carbohydr Res       Date:  1984-02-15       Impact factor: 2.104

5.  Differential effect of activated T amplifier cells on B cells responding to thymus-independent type 1 and type 2 antigens.

Authors:  H Braley-Mullen
Journal:  J Immunol       Date:  1982-08       Impact factor: 5.422

6.  Response of congenitally athymic (nude) and phenotypically normal mice to Cryptococcus neoformans infection.

Authors:  L K Cauley; J W Murphy
Journal:  Infect Immun       Date:  1979-03       Impact factor: 3.441

7.  Nonencapsulated Variant of Cryptococcus neoformans I. Virulence Studies and Characterization of Soluble Polysaccharide.

Authors:  T R Kozel; J Cazin
Journal:  Infect Immun       Date:  1971-02       Impact factor: 3.441

8.  Immunological unresponsiveness induced by cryptococcal capsular polysaccharide assayed by the hemolytic plaque technique.

Authors:  J W Murphy; G C Cozad
Journal:  Infect Immun       Date:  1972-06       Impact factor: 3.441

9.  Antibody-dependent leukocyte killing of Cryptococcus neoformans.

Authors:  G P Miller; S Kohl
Journal:  J Immunol       Date:  1983-09       Impact factor: 5.422

10.  Cryptococcal capsular polysaccharide-induced modulation of murine immune responses.

Authors:  J F Breen; I C Lee; F R Vogel; H Friedman
Journal:  Infect Immun       Date:  1982-04       Impact factor: 3.441

View more
  19 in total

1.  Proteins in the cell wall and membrane of Cryptococcus neoformans stimulate lymphocytes from both adults and fetal cord blood to proliferate.

Authors:  C H Mody; K L Sims; C J Wood; R M Syme; J C Spurrell; M M Sexton
Journal:  Infect Immun       Date:  1996-11       Impact factor: 3.441

2.  Immunosuppression, interleukin-10 synthesis and apoptosis are induced in rats inoculated with Cryptococcus neoformans glucuronoxylomannan.

Authors:  Laura S Chiapello; José L Baronetti; María P Aoki; Susana Gea; Héctor Rubinstein; Diana T Masih
Journal:  Immunology       Date:  2004-11       Impact factor: 7.397

3.  Immunogenicity and efficacy of Cryptococcus neoformans capsular polysaccharide glucuronoxylomannan peptide mimotope-protein conjugates in human immunoglobulin transgenic mice.

Authors:  Robert W Maitta; Kausik Datta; Andrew Lees; Shelley Sims Belouski; Liise-anne Pirofski
Journal:  Infect Immun       Date:  2004-01       Impact factor: 3.441

4.  Tissue localization of Cryptococcus neoformans glucuronoxylomannan in the presence and absence of specific antibody.

Authors:  D L Goldman; S C Lee; A Casadevall
Journal:  Infect Immun       Date:  1995-09       Impact factor: 3.441

Review 5.  Polysaccharide antigens of the capsule of Cryptococcus neoformans.

Authors:  R Cherniak; J B Sundstrom
Journal:  Infect Immun       Date:  1994-05       Impact factor: 3.441

6.  T-cell-dependent and T-cell-independent mechanisms of tolerance to glucuronoxylomannan of Cryptococcus neoformans serotype A.

Authors:  J B Sundstrom; R Cherniak
Journal:  Infect Immun       Date:  1993-04       Impact factor: 3.441

7.  Monoclonal antibodies reactive with immunorecessive epitopes of glucuronoxylomannan, the major capsular polysaccharide of Cryptococcus neoformans.

Authors:  Suzanne Brandt; Peter Thorkildson; Thomas R Kozel
Journal:  Clin Diagn Lab Immunol       Date:  2003-09

8.  Antibody-mediated protection in mice with lethal intracerebral Cryptococcus neoformans infection.

Authors:  J Mukherjee; L A Pirofski; M D Scharff; A Casadevall
Journal:  Proc Natl Acad Sci U S A       Date:  1993-04-15       Impact factor: 11.205

Review 9.  The capsule of the fungal pathogen Cryptococcus neoformans.

Authors:  Oscar Zaragoza; Marcio L Rodrigues; Magdia De Jesus; Susana Frases; Ekaterina Dadachova; Arturo Casadevall
Journal:  Adv Appl Microbiol       Date:  2009       Impact factor: 5.086

10.  Variation in the structure of glucuronoxylomannan in isolates from patients with recurrent cryptococcal meningitis.

Authors:  R Cherniak; L C Morris; T Belay; E D Spitzer; A Casadevall
Journal:  Infect Immun       Date:  1995-05       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.